is 145

IS-145 is a thromboxane A2 receptor antagonist.

QQN-00358 is a novel potent and selective tankyrase (TNKS) inhibitor.

K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 µM and Ki of 6.4 µM. K145 hydrochloride can induce apoptosis and has strong antitumor activity.

ML 145 is a selective and potent antagonist of human GPR35, with no significant activity against GPR35 in any of its immediate rodent homologs.ML 145 has potential anti-inflammatory activity for the study of immunoinflammation.ML 145 is a novel non-steroidal anti-inflammatory agent for the study of rheumatoid arthritis.

E3 Ligase Ligand-linker Conjugate 145 is a combination of an E3 ubiquitin ligase ligand and a linker, utilized in the synthesis of PROTACAR Degrader-7.

EGFR-IN-145 (compound 7c) is an EGFR kinase inhibitor. At a concentration of 20 μM, it inhibits wild-type EGFR kinase by 52.7%.

MMP-145 is used as a protease inhibitor.

LEB-03-145 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C5 alkyl linker [1] .

Hepatitis B Virus Pre-S Region (120-145) is a preS2 peptide that effectively blocks the attachment of single-chain Fv fragment (scFv) or IgG to recombinant Hepatitis B surface antigen (r-HBsAg) [1].

OP-145, a derivative of the antimicrobial peptide LL-37, is a synthetic antimicrobial peptide showing activity against E. coli, P. aeruginosa, C. albicans, and A. niger, with minimum inhibitory concentrations (MICs) of 2, 3, 6, and 18 µM, respectively. Utilizing poly(lactic-co-glycolic acid) (PLGA) microspheres loaded with OP-145 effectively prevents biofilm formation in a mouse model of bone infection, which is initiated by surgical femoral fracture and subsequent bacterial inoculation at the fracture site.

Anti-Mouse CD205 Antibody (NLDC-145) is an inhibitor designed to target mouse CD205.

OP-145 is a derivative of the antimicrobial peptide LL-37, known for its antibacterial properties against multiple MRSA strains. This compound is applicable in studies on chronic suppurative otitis media.

K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity. K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM.

Pico145 (HC-608) is a remarkable inhibitor of TRPC1/4/5 channels, specifically inhibiting ( )-englerin A-activated TRPC4/TRPC5 channels with IC50s of 0.349 and 1.3 nM in cells, while showing no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, or TRPM8.

FGA145 is a dual inhibitor of Mpro and human Cathepsin L, with Ki values of 3.71 μM for Mal-Mpro, 9.82 μM for pET21-Mpro, and 53 nM for Cathepsin L. Additionally, FGA145 exhibits multi-target antiviral activity.

T145 inhibits growth of Enterococcus faecalis, Staphylococcus aureus and Mycobacterium tuberculosis (Mtb) with sub μg/ml potencies that are potentially therapeutically valuable. T145 minimizes selection of spontaneous resistant mutants, a trait that prolo

MPT0L145 is a first-in-class PIK3C3/FGFR inhibitor.

TH-Z145 is a potent FPPS inhibitor for the study of myeloma and lung cancer.

Compound 1b, also known as Antibacterial agent 145, targets the bacterial iron uptake pathway to exert its effects. It compromises the integrity of the bacterial cytoplasmic membrane and inhibits cellular metabolism while demonstrating minimal cytotoxicity to normal cells [1].

Compound Ir5 (Antitumor agent-145) serves as a tumor inhibitor characterized by significant fluorescence and mitochondrial targeting. It promotes anti-cancer activity by inducing necroptosis and stimulating the necroptosis-related immune response [1].

CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).

MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).

Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).

Lidocaine (Alphacaine) is an amide local anesthetic with anti-inflammatory properties in vitro and in vivo. It has this functions perhaps due to an attenuation of intracellular adhesion molecule-1 (ICAM-1), pro-inflammatory cytokines, and reduction of neutrophils influx.